A Study of Anti-PD-L1 Antibody in Perioperative Chemotherapy of Esophageal Carcinoma.
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled Ib/Ⅱ clinical study to evaluate the
safety and effect of anti-PD-L1 antibody (ZKAB001) in perioperative chemotherapy of
esophageal squamous carcinoma in combination with Alb-paclitaxel and cisplatin. The
immunotherapy will be given before and after the operation every three weeks.